Dangshe Ma
Overview
Explore the profile of Dangshe Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez Bay A, Faulkner D, DaSilva J, Young T, Yang K, Giurleo J, et al.
Mol Cancer Ther
. 2023 Mar;
22(3):357-370.
PMID: 36861363
Most antibody-drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while ADCs that recycle to the plasma...
2.
Tavare R, Danton M, Giurleo J, Makonnen S, Hickey C, Arnold T, et al.
Cancer Immunol Res
. 2022 Jul;
10(10):1190-1209.
PMID: 35895745
Assessment of immune-cell subsets within the tumor immune microenvironment is a powerful approach to better understand cancer immunotherapy responses. However, the use of biopsies to assess the tumor immune microenvironment...
3.
Kelly M, Makonnen S, Hickey C, Arnold T, Giurleo J, Tavare R, et al.
J Immunother Cancer
. 2021 Jan;
9(1).
PMID: 33483343
Background: Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodies including cemiplimab have generated profound clinical activity across diverse cancer types. Tumorous PD-L1 expression, as assessed by immunohistochemistry (IHC),...
4.
Graziani E, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2068-2078.
PMID: 32747418
The approval of ado-trastuzumab emtansine (T-DM1) in HER2 metastatic breast cancer validated HER2 as a target for HER2-specific antibody-drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within...
5.
Betts A, Clark T, Jasper P, Tolsma J, van der Graaf P, Graziani E, et al.
J Pharmacokinet Pharmacodyn
. 2020 Jul;
47(5):513-526.
PMID: 32710210
A modeling and simulation approach was used for quantitative comparison of a new generation HER2 antibody drug conjugate (ADC, PF-06804103) with trastuzumab-DM1 (T-DM1). To compare preclinical efficacy, the pharmacokinetic (PK)/pharmacodynamic...
6.
Chiu D, Tavare R, Haber L, Aina O, Vazzana K, Ram P, et al.
Cancer Immunol Res
. 2020 Mar;
8(5):596-608.
PMID: 32184296
Patients with hematologic cancers have improved outcomes after treatment with bispecific antibodies that bind to CD3 on T cells and that redirect T cells toward cancer cells. However, clinical benefit...
7.
Zhang Q, Salzler R, Dore A, Yang J, Ma D, Olson W, et al.
J Proteome Res
. 2018 Oct;
17(11):3932-3940.
PMID: 30277784
The immune status of tumors critically influences their responsiveness to PD1 blockades and other immune-based therapies. Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is a clinically validated predictive biomarker of...
8.
Gupta P, Wentland J, Leal M, Ma D, Roach R, Esparza A, et al.
Oncotarget
. 2017 Sep;
8(34):57231-57245.
PMID: 28915667
Non-invasive imaging using radiolabels is a common technique used to study the biodistribution of biologics. Due to the limited shelf-life of radiolabels and the requirements of specialized labs, non-invasive optical...
9.
Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, et al.
Bioconjug Chem
. 2016 Jul;
27(8):1880-8.
PMID: 27412791
There is a considerable ongoing work to identify new cytotoxic payloads that are appropriate for antibody-based delivery, acting via mechanisms beyond DNA damage and microtubule disruption, highlighting their importance to...
10.
Tumey L, Charati M, He T, Sousa E, Ma D, Han X, et al.
Bioconjug Chem
. 2014 Sep;
25(10):1871-80.
PMID: 25216346
The stability of the connection between the antibody and the toxin can have a profound impact on ADC safety and efficacy. There has been increasing evidence in recent years that...